Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
ConditionAdvanced Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBioAtla, Inc.
About this trial
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
Age ≥ 18 years
Adequate renal function
Adequate liver function
Disqualifiers
Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have active autoimmune disease or a documented history of autoimmune disease.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
Trial design
Treatments tested in this trial
- BA3182
Treatment groups
168 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov